Comparison of immediate results and mid-term follow-up of surgical and percutaneous closure of ruptured sinus of Valsalva aneurysm

Abstract

Percutaneous closure is an attractive alternative to surgery in selected patients with ruptured sinus of Valsalva aneurysm for the better clinical advantages and economic benefits.

Long-Term Outcomes of Transcatheter Closure of Ruptured Sinus Valsalva Aneurysms Using Patent Ductus Arteriosus Occluders

“…Though the technique is still limited to a few heart centers with a small number of cases, the immediate and short to midterm follow-up results for TCC of RSVA are good. 6, 8 No serious complications were found in the follow-up period of the present study. Neither residual shunting nor AR was found at discharge or during the follow-up.…”

“…5-9 But to date, both large-scale and long-term follow-up results for this technique are scarce. 6, 8 Thus, the aim of the present study was to evaluate the safety and efficacy of TCC of RSVA and to characterize patients' long-term clinical outcomes.…”

Long-term failure of Amplatzer plugs in the treatment of aortic pathology

“…These cases demonstrate two major long‐term complications of AVP used in the management of aortic pathology, especially in patients with ruptured SOV aneurysms (RSVAs). Though surgical closure of ruptured SOV defects is the traditional gold standard, percutaneous techniques are an attractive alternative as they can provide similar success rates, and are less invasive, and can lower total medical costs compared to surgery . However, long‐term outcomes of percutaneous closures using Amplatzer devices in patients with both RSVAs and VSDs, including those with severe aortic regurgitation or pulmonary hypertension, are lacking.…”

Angiographic features of ruptured sinus of Valsalva aneurysm: New classification

“…There are 3 types of modified VSD occluders used in the study: small-waist double-disk occluders, muscular occluders, and asymmetric occluders. The diameter of the small-waist double-disk occluder is different in the left (aortic) and right (RA or RV) side disk [10]. The above occluders were approved by the State Food and Drug Administration (SFDA) of China in 2003, and received CE mark in 2008.…”

“…Surgical repair has been the mainstay of therapy with relatively low mortality [8,9]. However, some problems limit the application of surgical repair, for instance, severe hemodynamic instability and patch leak require a second operation [10]. Successful percutaneous closure has been increasingly reported, mainly as case reports or small series [11][12][13][14].…”